TORONTO, Oct. 12 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the third quarter, ended August 31, 2007.
"Our third quarter of fiscal 2007 was one of preparation as we worked towards moving our lead drug candidate AR001 into human clinical trials in 2008, while also building value in our business and our pipeline through the progression of our other antibody anti-cancer candidates," said Dr. David Young, President and CEO. "Our most important development this quarter and a milestone step for ARIUS, was the initiation of a pre-clinical dose-finding toxicology study for AR001, our CD44 targeting anti-cancer antibody."
CD44 Cancer Stem Cell Program
ARIUS initiated a pre-clinical dose-finding study, commencing its IND-enabling toxicology program for its lead anti-CD44 antibody. The Company expects to file a Phase I IND application and begin human clinical trials in 2008. The Company engaged a manufacturer for process development and manufacturing of its lead antibody under Current Good Manufacturing Practices ("cGMP").
Trop-2 Signal Transduction Program
ARIUS has successfully humanized its anti-Trop-2 antibody, which continues to retain its binding characteristics and in vivo activity. The Company also selected a manufacturer for the antibody. The Company expects to perform pre-clinical toxicology studies in 2008 in preparation for filing a Phase I IND application in 2008.
CD59 Complement Inhibitor Program
In collaboration with Antitope Limited, ARIUS has successfully humanized its CD59 targeting antibody, retaining its binding characteristics and in vivo activity. The Company expects to perform preclinical toxicology studies in 2008 in preparation for filing a Phase I IND application.
CD63 Antibody Program
|SOURCE ARIUS Research Inc.|
Copyright©2007 PR Newswire.
All rights reserved